Corresponding Author: Thomas A. Wadden, PhD, Perelman School of Medicine at the University of Pennsylvania, 3535 Market St, Ste 3027, Philadelphia, PA 19104 (wadden@pennmedicine.upenn.edu).
Accepted for Publication: February 4, 2021.
Published Online: February 24, 2021. doi:10.1001/jama.2021.1831
Author Contributions: Drs Wadden and Garvey had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. All authors had access to the trial results, and reviewed and approved the final version of the manuscript for publication.
Acquisition, analysis, or interpretation of data: All authors.
Drafting of the manuscript: Wadden, Billings, Koroleva, O'Neil, Rubino, Skovgaard, Garvey.
Critical revision of the manuscript for important intellectual content: All authors.
Statistical analysis: Skovgaard, Wallenstein.
Administrative, technical, or material support: Wadden, Rubino, Skovgaard.
Supervision: Wadden, Bailey, Koroleva, Skovgaard.
Conflict of Interest Disclosures: Dr Wadden reports receiving grants from Novo Nordisk (from grant support to the University of Pennsylvania) and personal fees from Novo Nordisk for service on a scientific advisory board during the conduct of the study, as well as personal fees from WW International (formerly Weight Watchers) for service on a scientific advisory board outside the submitted work. Dr Bailey reports receiving grants, personal fees, and nonfinancial support (writing assistance) from Novo Nordisk during the conduct of the study. Dr Billings reports receiving personal fees from Novo Nordisk, Sanofi, and Eli Lilly outside the submitted work. Dr Davies is co-funded by the NIHR Leicester Biomedical Research Centre and reports receiving consulting fees from Novo Nordisk; advisory board member, speaker, and consulting fees from Sanofi-Aventis, Eli Lilly, Merck Sharp & Dohme, Boehringer Ingelheim, AstraZeneca, and Janssen; advisory board fees from Lexicon, Servier, and Gilead Sciences Ltd; speaker fees from Napp Pharmaceuticals; and grants from Novo Nordisk, Sanofi-Aventis, Lilly, Boehringer Ingelheim, AstraZeneca, and Janssen outside the submitted work. Dr Frias reports receiving research support grants from Novo Nordisk during the conduct of the study; grants and personal fees from Boehringer Ingelheim, Eli Lilly, Merck, Novo Nordisk, and Sanofi; and grants from Janssen and Pfizer outside the submitted work. Dr Koroleva reports being an employee of Novo Nordisk A/S and holding shares in the company. Dr Lingvay reports receiving advisory board fees and consulting fees from AstraZeneca, consulting fees from Bayer HealthCare Pharmaceuticals, Eli Lilly and Company, Intarcia, Intercept Pharmaceuticals, Janssen Global Services, MannKind Corporation, Target Pharma, Valeritas, and Zealand Pharma; advisory board fees from Boehringer Ingelheim and Sanofi US Services; grant support, paid to UT Southwestern, from Merck; grant support, paid to her institution, from Mylan Pharmaceuticals and Pfizer; grant support, paid to UT Southwestern; and advisory board fees, consulting fees, and travel support from Novo Nordisk. Dr O'Neil reports receiving grants from Novo Nordisk during the conduct of the study; grants from Epitomee Medical, Eli Lilly, and WW International; and personal fees from Robard, Gedeon Richter, WebMD, and Novo Nordisk outside the submitted work. Dr Rubino reports receiving writing assistance from Novo Nordisk during the conduct of the study; serving as a clinical investigator for AstraZeneca, Boehringer Ingelheim, and Novo Nordisk; and reports owning Novo Nordisk shares of stock outside the submitted work. Dr Skovgaard reports spousal employment at Novo Nordisk. Dr Wallenstein reports receiving personal fees from Novo Nordisk during the conduct of the study and outside the submitted work. Dr Garvey reports receiving grants from Novo Nordisk; serving as site principal investigator for the clinical trial, which was sponsored by his university during the conduct of the study; receiving grants from Lexicon and Pfizer outside the submitted work; and serving as an ad hoc consultant on advisory committees for Jazz Pharmaceuticals, Boehringer Ingelheim, Novo Nordisk, and Pfizer. In each instance, he received no financial compensation, nor was there a financial relationship. No other disclosures were reported.
Funding/Support: This trial was funded by Novo Nordisk A/S.
Role of the Funders/Sponsors: Representatives of the sponsor (Novo Nordisk A/S) were involved in the design and conduct of the study; collection, management, analysis, and interpretation of the data; and preparation, review, and approval of the manuscript. Data were gathered by the site investigators, and the sponsor performed study site oversight, data collation, and analysis. A medical writer (Nicola Beadle, PhD, of Axis, a division of Spirit Medical Communications Group Ltd, funded by the sponsor) assisted with drafting the manuscript, under the direction of the authors. The sponsor did not have the right to veto publication or to control the decision regarding to which journal the manuscript was submitted. These decisions resided with the authors.
Group Information: A list of the STEP 3 Investigators appears in eAppendix 1 in Supplement 1.
Meeting Presentation: Presented at the 38th annual meeting of the Obesity Society, November 5, 2020.
Data Sharing Statement: See Supplement 4.
Additional Contributions: We thank all participants, investigators, and trial staff who were involved in the conduct of the trial, as well as Jena Tronieri, PhD, at the Perelman School of Medicine at the University of Pennsylvania, who was compensated by Novo Nordisk to supervise the delivery of intensive behavioral therapy by registered dietitians at the study sites. We also thank Lisa von Huth Smith, PhD (an employee of Novo Nordisk A/S) for review of and input to aspects related to patient-reported outcomes in the manuscript.
1.Jensen
MD , Ryan
DH , Apovian
CM ,
et al; American College of Cardiology/American Heart Association Task Force on Practice Guidelines; Obesity Society. 2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Obesity Society.
Circulation. 2014;129(25)(suppl 2):S102-S138. doi:
10.1161/01.cir.0000437739.71477.ee
PubMedGoogle ScholarCrossref 2.Heymsfield
SB , van Mierlo
CA , van der Knaap
HC , Heo
M , Frier
HI . Weight management using a meal replacement strategy: meta and pooling analysis from six studies.
Int J Obes Relat Metab Disord. 2003;27(5):537-549. doi:
10.1038/sj.ijo.0802258
PubMedGoogle ScholarCrossref 4.Wing
RR , Lang
W , Wadden
TA ,
et al; Look AHEAD Research Group. Benefits of modest weight loss in improving cardiovascular risk factors in overweight and obese individuals with type 2 diabetes.
Diabetes Care. 2011;34(7):1481-1486. doi:
10.2337/dc10-2415
PubMedGoogle ScholarCrossref 5.Garvey
WT , Mechanick
JI , Brett
EM ,
et al; Reviewers of the AACE/ACE Obesity Clinical Practice Guidelines. American Association of Clinical Endocrinologists and American College of Endocrinology comprehensive clinical practice guidelines for medical care of patients with obesity.
Endocr Pract. 2016;22(suppl 3):1-203. doi:
10.4158/EP161365.GL
PubMedGoogle ScholarCrossref 8.Kuna
ST , Reboussin
DM , Strotmeyer
ES ,
et al; Sleep AHEAD Research Subgroup of the Look AHEAD Research Group. Effects of weight loss on obstructive sleep apnea severity: ten-year results of the Sleep AHEAD study.
Am J Respir Crit Care Med. 2021;203(2):221-229. doi:
10.1164/rccm.201912-2511OC
PubMedGoogle ScholarCrossref 9.Wadden
TA , Walsh
OA , Berkowitz
RI ,
et al. Intensive behavioral therapy for obesity combined with liraglutide 3.0 mg: a randomized controlled trial.
Obesity (Silver Spring). 2019;27(1):75-86. doi:
10.1002/oby.22359
PubMedGoogle ScholarCrossref 10.Wadden
TA , Tronieri
JS , Sugimoto
D ,
et al. Liraglutide 3.0 mg and intensive behavioral therapy (IBT) for obesity in primary care: the SCALE IBT randomized controlled trial.
Obesity (Silver Spring). 2020;28(3):529-536. doi:
10.1002/oby.22726
PubMedGoogle ScholarCrossref 12.Ahmann
AJ , Capehorn
M , Charpentier
G ,
et al. Efficacy and safety of once-weekly semaglutide versus exenatide ER in subjects with type 2 diabetes (SUSTAIN 3): a 56-week, open-label, randomized clinical trial.
Diabetes Care. 2018;41(2):258-266. doi:
10.2337/dc17-0417
PubMedGoogle ScholarCrossref 13.Ahrén
B , Masmiquel
L , Kumar
H ,
et al. Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as an add-on to metformin, thiazolidinediones, or both, in patients with type 2 diabetes (SUSTAIN 2): a 56-week, double-blind, phase 3a, randomised trial.
Lancet Diabetes Endocrinol. 2017;5(5):341-354. doi:
10.1016/S2213-8587(17)30092-X
PubMedGoogle ScholarCrossref 14.O’Neil
PM , Birkenfeld
AL , McGowan
B ,
et al. Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial.
Lancet. 2018;392(10148):637-649. doi:
10.1016/S0140-6736(18)31773-2
PubMedGoogle ScholarCrossref 18.Wharton
S , Astrup
A , Endahl
L ,
et al. Estimating and reporting treatment effects in clinical trials for weight management: using estimands to interpret effects of intercurrent events and missing data.
Int J Obes (Lond). Published online January 18, 2021. doi:
10.1038/s41366-020-00733-x
PubMedGoogle Scholar 23.Leibel
RL , Seeley
RJ , Darsow
T , Berg
EG , Smith
SR , Ratner
R . Biologic responses to weight loss and weight regain: report from an American Diabetes Association research symposium.
Diabetes. 2015;64(7):2299-2309. doi:
10.2337/db15-0004
PubMedGoogle ScholarCrossref 27.Friedrichsen
M , Breitschaft
A , Tadayon
S , Wizert
A , Skovgaard
D . The effect of semaglutide 2.4 mg once weekly on energy intake, appetite, control of eating, and gastric emptying in adults with obesity.
Diabetes Obes Metab. 2021;23(3):754-762. doi:
10.1111/dom.14280PubMedGoogle ScholarCrossref 28.Bettge
K , Kahle
M , Abd El Aziz
MS , Meier
JJ , Nauck
MA . Occurrence of nausea, vomiting and diarrhoea reported as adverse events in clinical trials studying glucagon-like peptide-1 receptor agonists: a systematic analysis of published clinical trials.
Diabetes Obes Metab. 2017;19(3):336-347. doi:
10.1111/dom.12824
PubMedGoogle ScholarCrossref 31.Wilding
JPH , Batterham
RL , Calanna
S ,
et al; the STEP 1 Study Group. Once-weekly semaglutide in adults with overweight or obesity.
N Engl J Med. Published February 10, 2021. doi:
10.1056/NEJMoa2032183Google Scholar